Jennifer S. Chadwick, PhD, is director of biologic development at BioAnalytix.
De-risking Biologics Development Through Advanced Mass Spectrometry Approaches
Advanced HDX-MS and native MS techniques can be used to improve the identification of potentially successful biologic drugs and take the risk out of CMC and clinical designs.
Using advanced HDX-MS and native MS techniques can improve the identification of potentially successful biologic drugs and de-risk CMC and clinical designs.